NKMAX Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public, Subsidiary
- Established
- 2002-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.nkmax.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment
Phase 1
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- NKMAX Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04872634
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of
News
No news found